Adenosine A2A antagonists in parkinson's disease: What's next?

Current Neurology and Neuroscience Reports

Volumn 12, Issue 4, 2012, Pages 376-385

  Hickey, Patrick ^a   Stacy, Mark ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

A2A; Adenosine; Adenosine antagonists; Dyskinesias; Istradefylline; Motor fluctuations; Neuroprotection; Parkinson's disease; Preladenant; SYN115

Indexed keywords

ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR BLOCKING AGENT; BENSERAZIDE PLUS LEVODOPA; DOPAMINE; ISTRADEFYLLINE; LEVODOPA; PLACEBO; PRELADENANT; ST 1535; TOZADENANT; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BASAL GANGLION; DISEASE MODEL; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DYSKINESIA; HUMAN; LOW DRUG DOSE; MOLECULAR INTERACTION; MOTOR DYSFUNCTION; NEUROANATOMY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN FUNCTION; TREATMENT OUTCOME; TREMOR;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; BASAL GANGLIA; DISEASE MODELS, ANIMAL; HUMANS; LEVODOPA; PARKINSON DISEASE; RECEPTOR, ADENOSINE A2A;

EID: 84865640480     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-012-0279-2     Document Type: Article

References (73)

1. Stacy M. Medical treatment of Parkinson disease. Neurol Clin. 2009;27(3):605-31. v.
2. Lewitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med. 2008;359(23):2468-76.
3. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384-6. (Pubitemid 46184217)
4. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12(10):366-75. (Pubitemid 19238787)
5. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci. 2006;29(11):647-54. (Pubitemid 44602262)
6. Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferré S. Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol. 2007;83(5):277-92. (Pubitemid 350110609)
7. Daly JW, Butts-Lamb P, Padgett W. Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines. Cell Mol Neurobiol. 1983;3(1):69-80. (Pubitemid 13014444)
8. Schiffmann SN, Jacobs O, Vanderhaeghen JJ. Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study. J Neurochem. 1991;57(3):1062-7.
9. Rosin DL, Robeva A, Woodard RL, Guyenet PG, Linden J. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J Comp Neurol. 1998;401(2):163-86. (Pubitemid 28481960)
10. Morelli M, Carta AR, Kachroo A, Schwarzschild M.A. Pathophysiological roles for purines: adenosine, caffeine and urate. Prog Brain Res. 2010;183:183-208.
11. Augood SJ, Emson PC. Adenosine A2a receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: a co-expression study. Brain Res Mol Brain Res. 1994;22 (1-4):204-10.
12. Hettinger BD, Lee A, Linden J, Rosin DL. Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J Comp Neurol. 2001;431(3):331-46. (Pubitemid 32115298)
13. Kurokawa M, Koga K, Kase H, Nakamura J, Kuwana Y. Adenosine A2a receptor-mediated modulation of striatal acetylcholine release in vivo. J Neurochem. 1996;66(5):1882-8.
14. Gerfen CR. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci. 1992;15:285-320.
15. Ochi M, Shiozaki S, Kase H. Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease. Neuroscience. 2004;127(1):223-31. (Pubitemid 38829167)
16. Shindou T, Richardson PJ, Mori A, Kase H, Ichimura M. Adenosine modulates the striatal GABAergic inputs to the globus pallidus via adenosine A2A receptors in rats. Neurosci Lett. 2003;352(3):167-70. (Pubitemid 38367594)
17. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990;13(7):281-5.
18. Obeso JA, Lanciego JL. Past, present, and future of the pathophysiological model of the Basal Ganglia. Front Neuroanat. 2011;5:39.
19. Ferré S, Borycz J, Goldberg SR, Hope BT, Morales M, Lluis C, et al. Role of adenosine in the control of homosynaptic plasticity in striatal excitatory synapses. J Integr Neurosci. 2005;4(4):445-64. (Pubitemid 43091301)
20. Newman EA. New roles for astrocytes: regulation of synaptic transmission. Trends Neurosci. 2003;26(10):536-42. (Pubitemid 37176908)
21. Hertz L, Zielke HR. Astrocytic control of glutamatergic activity: astrocytes as stars of the show. Trends Neurosci. 2004;27(12):735-43. (Pubitemid 39488077)
22. Mori A, Shindou T. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology. 2003;61(11 Suppl 6):S44-8. (Pubitemid 37505546)
23. Ferré S, Rubio A, Fuxe K. Stimulation of adenosine A2 receptors induces catalepsy. Neurosci Lett. 1991;130(2):162-4.
24. Kanda T, Shiozaki S, Shimada J, Suzuki F, Nakamura J. KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Eur J Pharmacol. 1994;256(3):263-8. (Pubitemid 24134887)
25. Kanda T, Tashiro T, Kuwana Y, Jenner P. Adenosine A2A receptors modifymotor function inMPTP-treated commonmarmosets. Neuroreport. 1998a;9(12):2857-60. (Pubitemid 28435177)
26. Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y. Actions of adenosine A2A receptor antagonist KW- 6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl). 1999;147(1):90-5. (Pubitemid 30010028)
27. Hauber W, Neuscheler P, Nagel J, Müller CE. Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A(2A) receptors in the caudate-putamen of rats. Eur J Neurosci. 2001;14(8):1287-93. (Pubitemid 35463735)
28. Rose S, Ramsay Croft N, Jenner P. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats. Brain Res. 2007;1133(1):110-4. (Pubitemid 46123239)
29. Wardas J, Konieczny J, Lorenc-Koci E. SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats. Synapse. 2001;41(2):160-71.
30. Hodgson RA, Bertorelli R, Varty GB, Lachowicz JE, Forlani A, Fredduzzi S, et al. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2- [4-2,4-difluorophenyl]-1- piperazinyl]ethyl]-2-(2-furanyl)-7 Hpyrazolo[ 4,3-e][1,2,4]triazolo[1,5-c] pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Ther. 2009;330(1):294-303.
31. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol. 1998(b) Apr;43(4):507-13. (Pubitemid 28231727)
32. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, et al. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTPtreated monkeys. Exp Neurol. 2000;162(2):321-7. (Pubitemid 30217727)
33. Hodgson RA, Bedard PJ, Varty GB, Kazdoba TM, Di Paolo T, Grzelak ME, et al. Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders. Exp Neurol. 2010;225(2):384-90.
34. Halldner L, Lozza G, Lindström K, Fredholm BB. Lack of tolerance to motor stimulant effects of a selective adenosine A(2A) receptor antagonist. Eur J Pharmacol. 2000;406(3):345-54.
35. Pinna A, Fenu S,MorelliM.Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse. 2001;39(3):233-8. (Pubitemid 32099678)
36. Jenner P. A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology. 2003;61(11 Suppl 6): S32-8. (Pubitemid 37505544)
37. Simola N, Fenu S, Baraldi PG, Tabrizi MA, Morelli M. Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp Neurol. 2004;189(1):182-8. (Pubitemid 39024467)
38. Correa M, Wisniecki A, Betz A, Dobson DR, O'Neill MF, O'Neill MJ, et al. The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res. 2004;148(1-2):47-54. (Pubitemid 37543655)
39. Pinna A, Corsi C, Carta AR, Valentini V, Pedata F, Morelli M. Modification of adenosine extracellular levels and adenosine A (2A) receptor mRNA by dopamine denervation. Eur J Pharmacol. 2002;446(1-3):75-82. (Pubitemid 34722559)
40. Koga K, Kurokawa M, Ochi M, Nakamura J, Kuwana Y. Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur J Pharmacol. 2000;408(3):249-55.
41. Tronci E, Simola N, Borsini F, Schintu N, Frau L, Carminati P, et al. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol. 2007;566(1-3):94-102. (Pubitemid 46782796)
42. Fredduzzi S, Moratalla R,Monopoli A, Cuellar B, Xu K, Ongini E, et al. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci. 2002;22(3):1054-62. (Pubitemid 34141785)
43. Xiao D, Bastia E, Xu YH, Benn CL, Cha JH, Peterson TS, et al. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine- induced dyskinesia in hemiparkinsonian mice. J Neurosci. 2006;26(52):13548-55. (Pubitemid 46026487)
44. Bastia E, Xu YH, Scibelli AC, Day YJ, Linden J, Chen JF, et al. A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization. Neuropsychopharmacology. 2005;30(5):891-900. (Pubitemid 40570905)
45. Bibbiani F, Oh JD, Petzer JP, Castagnoli Jr N, Chen JF, Schwarzschild MA, et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp Neurol. 2003;184(1):285-94. (Pubitemid 37444038)
46. Lundblad M, Vaudano E, Cenci M.A. Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. J Neurochem. 2003;84 (6):1398-410. (Pubitemid 36343606)
47. Rao N, Uchimura T, Mori A. Evaluation of safety, tolerability, and multiple dose pharma- cokinetics of istradephylline in healthy subjects. Clin Pharmacol Ther. 2005a;83(Suppl):PIII-89
48. Rao N, Uchimura T, Mori A. Evaluation of safety, tolerability, and multiple dose pharmacokinetics of istradephylline in Parkinson's disease patients. Clin Pharmacol Ther. 2005b;83(Suppl):PIII-88
49. Brooks DJ, Doder M, Osman S, Luthra SK, Hirani E, Hume S, et al. Positron emission tomography analysis of [11 C]KW-6002 binding to human and rat adenosine A2A receptors in the brain. Synapse. 2008;62(9):671-81. (Pubitemid 352032542)
50. Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology. 2003;61(3):293-6. (Pubitemid 36975954)
51. Hauser RA, Hubble JP, Truong DD. Istradefylline US-001 Study Group. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology. 2003;61(3):297-303.
52. LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, et al. 6002-US-005 Study Group. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63(3):295-302. (Pubitemid 351499859)
53. Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008;70(23):2233-40.
54. Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M. Japanese Istradefylline Study Group. Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: a randomized, controlled study. Mov Disord. 2010;25(10):1437-43.
55. Factor S, Mark MH, Watts R, Struck L, Mori A, Ballerini R, et al. Istradefylline 6002-US-007 Study Group. A long-term study of istradefylline in subjects with fluctuating Parkinson's disease. Parkinsonism Relat Disord. 2010;16(6):423-6.
56. Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, et al. Istradefylline 6002-US-013 Study Group. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord. 2008;23(15):2177-85.
57. Pourcher E, Fernandez HH, Stacy M, Mori A, Ballerini R, Chaikin P. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study. Parkinsonism Relat Disord. 2011 Oct 12.
58. Fernandez HH, Greeley DR, Zweig RM, Wojcieszek J, Mori A, Sussman NM. 6002-US-051 Study Group. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat Disord. 2010;16(1):16
59. FDA Issues Not Approvable Letter for Istradefylline. http://www.drugs. com/nda/kw-6002-080228.html.
60. Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, et al. Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol. 2011;10(3):221-9.
61. Black KJ, Koller JM, Campbell MC, Gusnard DA, Bandak SI. Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease. J Neurosci. 2010;30 (48):16284-92.
62. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000;283(20):2674-9. (Pubitemid 30337329)
63. Ascherio A, Zhang SM, Hernán MA, Kawachi I, Colditz GA, Speizer FE, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol. 2001;50(1):56-63.
64. Hancock DB, Martin ER, Stajich JM, Jewett R, Stacy MA, Scott BL, et al. Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. Arch Neurol. 2007;64 (4):576-80. (Pubitemid 46588348)
65. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J. Coffee and tea consumption and the risk of Parkinson's disease. Mov Disord. 2007;22(15):2242-8.
66. Sääksjärvi K, Knekt P, Rissanen H, Laaksonen MA, Reunanen A, Männistö S. Prospective study of coffee consumption and risk of Parkinson's disease. Eur J Clin Nutr. 2008;62(7):908-15. (Pubitemid 351982874)
67. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci. 2001;21(10): RC143.
68. Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J Neurochem. 2002;80(2):262-70. (Pubitemid 34809371)
69. Xu K, Xu YH, Chen JF, Schwarzschild M.A. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neurosci Lett. 2002;322(1):13-6. (Pubitemid 34215019)
70. Yu L, Shen HY, Coelho JE, Araújo IM, Huang QY, Day YJ, et al. Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol. 2008;63 (3):338-46. (Pubitemid 351499863)
71. Fiebich BL, Biber K, Lieb K, van Calker D, Berger M, Bauer J, et al. Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia. 1996;18(2):152-60.
72. Saura J, Angulo E, Ejarque A, Casadó V, Tusell JM, Moratalla R, et al. Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem. 2005;95 (4):919-29. (Pubitemid 41713478)
73. Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, Brooks DJ. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology. 2011;76(21):1811-6.